Mechanism of ochratoxin A stimulated lipid peroxidation RF Omar, BB Hasinoff, F Mejilla, AD Rahimtula Biochemical Pharmacology 40 (6), 1183-1191, 1990 | 171 | 1990 |
In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses J Piret, J Lamontagne, J Bestman-Smith, S Roy, P Gourde, A Désormeaux, ... Journal of clinical microbiology 38 (1), 110-119, 2000 | 166 | 2000 |
Role of cytochrome P‐450 in ochratoxin a‐stimulated lipid peroxidation RF Omar, AD Rahimtula, H Bartsch Journal of Biochemical Toxicology 6 (3), 203-209, 1991 | 75 | 1991 |
Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A RF Omar, HV Gelboin, AD Rahimtula Biochemical pharmacology 51 (3), 207-216, 1996 | 68 | 1996 |
Thermoreversible Gel Formulations Containing Sodium Lauryl Sulfate or n-Lauroylsarcosine as Potential Topical Microbicides against Sexually Transmitted Diseases S Roy, P Gourde, J Piret, A Désormeaux, J Lamontagne, C Haineault, ... Antimicrobial agents and chemotherapy 45 (6), 1671-1681, 2001 | 52 | 2001 |
Comparative Study of Mechanisms of Herpes Simplex Virus Inactivation by Sodium Lauryl Sulfate and n-Lauroylsarcosine J Piret, S Roy, M Gagnon, S Landry, A Désormeaux, RF Omar, ... Antimicrobial Agents and Chemotherapy 46 (9), 2933-2942, 2002 | 49 | 2002 |
NADPH-cytochrome-P-450 reductase promoted hydroxyl radical production by the iron (III)-ochratoxin A complex BB Hasinoff, AD Rahimtula, RF Omar Biochimica et Biophysica Acta (BBA)-General Subjects 1036 (1), 78-81, 1990 | 48 | 1990 |
Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9 N Gagné, H Cormier, RF Omar, A Désormeaux, P Gourde, MJ Tremblay, ... Sexually transmitted diseases 26 (3), 177-183, 1999 | 44 | 1999 |
Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device C Haineault, P Gourde, S Perron, A Désormeaux, J Piret, RF Omar, ... Biology of reproduction 69 (2), 687-694, 2003 | 38 | 2003 |
A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom® formulations in Cameroonian women FX Mbopi-Keou, S Trottier, RF Omar, NN Nkele, S Fokoua, ER Mbu, ... Contraception 81 (1), 79-85, 2010 | 35 | 2010 |
Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment J Bestman-Smith, J Piret, A Désormeaux, MJ Tremblay, RF Omar, ... Antimicrobial agents and chemotherapy 45 (8), 2229-2237, 2001 | 31 | 2001 |
Ribavirin potentiates the efficacy and toxicity of 2', 3'-dideoxyinosine in the murine acquired immunodeficiency syndrome model. P Harvie, RF Omar, N Dusserre, N Lansac, A Desormeaux, P Gourde, ... Journal of Pharmacology and Experimental Therapeutics 279 (2), 1009-1017, 1996 | 28 | 1996 |
Applicator for the delivery of topical formulations into mucosal cavities MG Bergeron, A Desormeaux, RF Omar US Patent 7,465,295, 2008 | 27 | 2008 |
Safety, tolerance and acceptability of the Invisible Condom® and its vaginal applicator in healthy women and their male sexual partners S Trottier, RF Omar, A Désormeaux, J Drouin, MT Gagnon, F Vezina, ... Contraception 76 (2), 117-125, 2007 | 25 | 2007 |
The future of microbicides RF Omar, MG Bergeron International Journal of Infectious Diseases 15 (10), e656-e660, 2011 | 24 | 2011 |
Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2 J Piret, N Gagne, S Perron, A Desormeaux, MJ Tremblay, P Gourde, ... Sexually transmitted diseases 28 (8), 484-491, 2001 | 21 | 2001 |
Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations … MG Bergeron, A Désormeaux, RF Omar, J Juhasz US Patent 6,500,460, 2002 | 20 | 2002 |
Distribution of a vaginal gel (Invisible Condom®) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators … RF Omar, S Trottier, G Brousseau, A Lamarre, A Gagnon, MG Bergeron Contraception 77 (6), 447-455, 2008 | 18 | 2008 |
Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations … MG Bergeron, A Désormeaux, RF Omar, J Juhasz US Patent 7,192,607, 2007 | 18 | 2007 |
Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model P Harvie, RF Omar, N Dusserre, A Désormeaux, P Gourde, M Tremblay, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 12 (5), 451-461, 1996 | 17 | 1996 |